BD MGIT™ TBc Identification Test
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), recently launched in the BD MGIT™ TBc Identification Test in Africa and the European Union (EU) to identify M. tuberculosis complex (Mtbc) from liquid culture.Specifically, the new product detects MPT64, a mycobacterial protein that is secreted by Mtbc cells during culture.The new test is very simple to use, providing accurate and reliable results in only 15 minutes.The faster time to result is a significant improvement over the several hours or days required by other available tests.
According to the WHO, it is imperative that all mycobacterial isolates be speciated at least to the level of Mtbc vs. non-tuberculous mycobacteria (NTM) and that a rapid and affordable method of species identification be used.NTM refers to all the species in the family of mycobacteria that do not cause tuberculosis.Timely identification of Mtbc can accurately guide initial therapy and help lead to better patient outcomes.
About BD’s Tuberculosis Diagnostics
The BD MGIT™ TBc Identification Test is the newest addition to BD’s line of products designed to help diagnose tuberculosis.
The BD BACTEC™ MGIT™ System utilizes liquid culture and dramatically shortens mycobacteria culture recovery time to approximately 10-14 days, compared with up to six weeks for traditional solid culture. In 2007, the WHO adopted a policy recommending the use of liquid culture methods in resource-limited settings and as a standard of care for TB diagnosis and patient management. 1For more information on BD’s work in addressing Tuberculosis, please visit http://bd.com/globalhealth/tb.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people\'s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD\'s capabilities are instrumental in combating many of the world\'s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.